Overcoming size barriers in retinal gene therapy via lipid nanoparticle-mediated delivery of full-length eys DNA
- 28 January 2026
- journal article
- research article
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 16 (8) , 2921-2936
Abstract
Gene augmentation for inherited retinal diseases (IRDs) is constrained by the limited packaging capacity of viral vectors, rendering large genes such as EYS inaccessible to conventional delivery platforms. Here, we demonstrate a non-viral lipid nanoparticle (LNP) strategy for the intracellular delivery and transcription of full-length EYS plasmid DNA (~ 11.6 kb), a gene implicated in autosomal recessive retinitis pigmentosa. An LNP formulation based on the ionizable lipid KC2 and DOPC was first optimized using an eGFP reporter construct, achieving high encapsulation efficiency and robust transgene expression in ARPE-19 cells. The same formulation encapsulating the EYS construct showed single-copy loading and structural stability in human vitreous, while confocal imaging and RT-qPCR verified functional delivery in retinal pigment epithelial (RPE) cell cultures. In an ex vivo bovine retinal explant, laser capture microdissection followed by RT-qPCR of the photoreceptor layer confirmed EYS mRNA expression after mimicking subretinal injection. This provides direct evidence of nuclear plasmid delivery in retinal tissue, which closely preserves the laminar structure and cellular composition of the human retina. To our knowledge, this is the first report of in vitro/ex vivo LNP-mediated delivery of a large (> 10 kbp) full-length IRD-relevant gene, underscoring the potential of LNPs for overcoming the size constraints of current gene therapies. Graphical AbstractKeywords
Funding Information
- European Joint Programme Rare Diseases (G0H7520N)
- Fonds Wetenschappelijk Onderzoek (1226224N)
- Fonds Wetenschappelijk Onderzoek (1S19723N)
- Fonds Wetenschappelijk Onderzoek (K110523N)
- Fonds Wetenschappelijk Onderzoek (K143424N)
- ARVO Foundation for Eye Research (K128824N)
- ARVO Foundation for Eye Research (K118625N)
This publication has 60 references indexed in Scilit:
- Enhancing non-viral DNA delivery systems: Recent advances in improving efficiency and target specificityJournal of Controlled Release, 2024
- Plasmid DNA ionisable lipid nanoparticles as non-inert carriers and potent immune activators for cancer immunotherapyJournal of Controlled Release, 2024
- Determination of mRNA copy number in degradable lipid nanoparticles via density contrast analytical ultracentrifugationEuropean Biophysics Journal, 2023
- Next‐Generation Vaccines: Nanoparticle‐Mediated DNA and mRNA DeliveryAdvanced Healthcare Materials, 2021
- Fluorescence‐Based Quantification of Messenger RNA and Plasmid DNA Decay Kinetics in Extracellular Biological Fluids and Cell ExtractsAdvanced Biosystems, 2020
- Lipid nanoparticles for delivery of messenger RNA to the back of the eyeJournal of Controlled Release, 2019
- Effective delivery of large genes to the retina by dual AAV vectorsEMBO Molecular Medicine, 2013
- Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivoJournal of Controlled Release, 2013
- Identification of a 2 Mb Human Ortholog of Drosophila eyes shut/spacemaker that Is Mutated in Patients with Retinitis PigmentosaThe American Journal of Human Genetics, 2008
- Retinitis pigmentosaSurvey of Ophthalmology, 1988